Exendin 9 39

PEG200, HCl, Pefabloc, and acetaminophen were purchased from Sigma Aldrich (Cat. No. P3015, 1.00317, 76,307, and A7085; Soborg, Denmark). BIBO3304 (Y1 antagonist), BIIE0246 (Y2 antagonists), and BIBN4096 (CGRP antagonist) were purchased from Tocris (Cat. No. 2412, 1700 and 4561; Bristol, UK). Somatostatin receptor antagonist was purchased from Bachem (iSST, Cat. No. BIM-23627; Bubendorf, Switzerland). Exendin 4 (Ex4) and Exendin (9–39) (Ex(9–39)) were both purchased from Anaspec (Cat. No. ANA24463 and ANA24467; Cambridge Bioscience, Cambridge, UK). Obestatin was kindly provided by Annette Beck-Sickinger and synthesized as previously described [12 (link)]. ELISAs for GLP-1 and insulin were obtained from MesoScale (Cat. No. L4503PA and K152BZC; MesoScale Diagnostics, Maryland, USA). GIP and total ghrelin were acquired from Merck/Millipore (Cat. No. EZRMGIP-55K and EZRGRT-91K; Merck/Millipore Darmstadt, Germany). PYY ELISA was purchased from Crystal Chem (Cat. No. 81501; Zaandam, Netherlands). An acetaminophen kit was obtained from Sekisui Diagnostics (Cat. No. 506–10; Sekisui, Lexington, MA, USA). Cpd1324 was synthesized by InterBioScreen Ltd. as previously described [10 (link)] and formulated with a vehicle containing 3.2 μM (−5.5 M) of zinc ions for all of the in vivo experiments.